Relay Therapeutics/$RLAY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Ticker
$RLAY
Sector
Primary listing
Employees
193
Headquarters
Website
RLAY Metrics
BasicAdvanced
$4.3bn
-
-$1.57
1.75
-
Price and volume
Market cap
$4.3bn
Beta
1.75
52-week high
$20.20
52-week low
$3.03
Average daily volume
4.6m
Financial strength
Current ratio
22.132
Quick ratio
21.581
Long term debt to equity
4.31
Total debt to equity
4.916
Profitability
EBITDA (TTM)
-293.606
Gross margin (TTM)
-2,300.34%
Net profit margin (TTM)
-2,554.37%
Operating margin (TTM)
-2,776.87%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-24.72%
Return on equity (TTM)
-40.01%
Valuation
Price to revenue (TTM)
322.175
Price to book
5.82
Price to tangible book (TTM)
5.82
Price to free cash flow (TTM)
-16.119
Free cash flow yield (TTM)
-6.20%
Free cash flow per share (TTM)
-1.225
Growth
Revenue change (TTM)
39.03%
Earnings per share change (TTM)
-28.42%
3-year revenue growth (CAGR)
107.90%
3-year earnings per share growth (CAGR)
-17.57%
What the Analysts think about RLAY
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
RLAY Financial Performance
Revenues and expenses
RLAY Earnings Performance
Company profitability
RLAY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs